デフォルト表紙
市場調査レポート
商品コード
1231755

間葉系幹細胞(MSC)の世界市場

Mesenchymal Stem Cells (MSC)

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 202 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
間葉系幹細胞(MSC)の世界市場
出版日: 2023年03月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 202 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

間葉系幹細胞(MSC)の世界市場は、2030年に95億米ドルに達する

COVID-19後の変化したビジネス環境において、2022年に38億米ドルと予測される間葉系幹細胞(MSC)の世界市場は、2022年から2030年にかけてCAGR12.1%で成長し、2030年までに95億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである骨髄は、CAGR13.5%を記録し、分析期間終了時には31億米ドルに達すると予測されます。パンデミック後の回復を考慮し、脂肪組織セグメントの成長は、今後8年間のCAGRが15.6%に修正されました。

米国市場は11億米ドル、中国はCAGR11.4%の成長予測

米国の間葉系幹細胞(MSC)市場は、2022年には11億米ドルに達すると推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが11.4%となり、2030年には16億米ドルの市場規模に達すると予測されます。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ10%と9.7%の成長が予測されています。欧州では、ドイツがCAGR7.4%で成長すると予測されています。

調査対象企業の例

  • Cell Applications Inc.
  • Celprogen Inc.
  • Cyagen US Inc.
  • Genlantis Inc.
  • Lonza Group
  • Mesoblast Limited
  • MilliporeSigma
  • Neuromics
  • Orthofix International N.V.
  • PromoCell GmbH
  • R&D Systems Inc.
  • ScienCell Research Laboratories
  • Stemcell Technologies Inc.
  • Stemedica Cell Technologies Inc.
  • Thermo Fischer Scientific Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP-7815

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Mesenchymal Stem Cells (MSC) Market to Reach $9.5 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Mesenchymal Stem Cells (MSC) estimated at US$3.8 Billion in the year 2022, is projected to reach a revised size of US$9.5 Billion by 2030, growing at aCAGR of 12.1% over the period 2022-2030. Bone Marrow, one of the segments analyzed in the report, is projected to record 13.5% CAGR and reach US$3.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Adipose Tissues segment is readjusted to a revised 15.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $1.1 Billion, While China is Forecast to Grow at 11.4% CAGR

The Mesenchymal Stem Cells (MSC) market in the U.S. is estimated at US$1.1 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 11.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10% and 9.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR.

Select Competitors (Total 56 Featured):

  • Cell Applications Inc.
  • Celprogen Inc.
  • Cyagen US Inc.
  • Genlantis Inc.
  • Lonza Group
  • Mesoblast Limited
  • MilliporeSigma
  • Neuromics
  • Orthofix International N.V.
  • PromoCell GmbH
  • R&D Systems Inc.
  • ScienCell Research Laboratories
  • Stemcell Technologies Inc.
  • Stemedica Cell Technologies Inc.
  • Thermo Fischer Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Mesenchymal Stem Cells Market on a Rapid Growth Path
    • Recent Market Activity
    • Current and Future Analysis
    • The Present and Future of MSC Therapies
    • Select MSC-based Therapeutics
    • Mesenchymal Stem Cell Research
    • Completed Phase III Studies with MSCs
    • MSCs are Being Explored for Several New Treatment Possibilities
    • Widespread Commercialization of 'Off-the-Shelf' MSCs to Become a Reality
    • Software Companies Endeavour to Cash in on the Boom
    • Mesenchymal Stem Cells (MSC) - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • Cell Applications, Inc. (USA)
    • Celprogen, Inc. (USA)
    • Cyagen US Inc. (USA)
    • Genlantis, Inc. (USA)
    • Lonza Group (Switzerland)
    • Mesoblast Limited (Australia)
    • MilliporeSigma (USA)
    • Neuromics (USA)
    • Orthofix International N.V. (Italy)
    • PromoCell GmbH (Germany)
    • R&D Systems, Inc. (USA)
    • ScienCell Research Laboratories (USA)
    • Stemcell Technologies Inc. (Canada)
    • Stemedica Cell Technologies, Inc. (USA)
    • Thermo Fischer Scientific, Inc. (USA)
    • Vitro Biopharma (USA)
  • 3. MARKET TRENDS & DRIVERS
    • Development of Regenerative Medicine Accelerates Demand for MSCs
    • Ageing Demographics to Drive Demand for Mesenchymal Stem Cell Therapies
    • Global Aging Population Statistics - Opportunity Indicators
    • Growing Prevalence of Chronic Diseases Propels Demand for Mesenchymal Stem Cells
    • Key Disease Statistics - Opportunity Indicators
    • Growing Volume of Orthopedic Procedures: An Opportunity for the MSC Market
    • Adult Stem Cell Therapies on Growth Trajectory, as Controversies Continue to Haunt Embryonic Stem Cell Research
    • Adult Stem Cells and Embryonic Stem Cells - A Comparison
    • MSCs Versus Embryonic or Induced Pluripotent Stem Cells
    • MSC Therapies - Immune to Ethical Issues Applicable to Embryonic Stem Cells
    • MSCs - A Potential Vehicle for 'Targeted Drug Delivery'
    • Stem Cell Based Bone Grafts: Promising Growth Ahead
    • Loopholes Associated with In Vivo Properties Constrain Therapeutic Advancements
    • Major Challenges Confronting Mesenchymal Stem Cell Market
    • Allogeneic MSCs - Offering Promise in Immunosuppressive and Tissue Repair Therapy
    • Administration Route Determines the Effectiveness of MSCs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Mesenchymal Stem Cells (MSC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Bone Marrow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Bone Marrow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Adipose Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Adipose Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Adipose Tissues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Fetal Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Fetal Liver by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Fetal Liver by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Lung by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Cord Blood by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Cord Blood by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Sources of MSC Isolation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Sources of MSC Isolation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Sources of MSC Isolation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Disease Modelling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Disease Modelling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 27: World 16-Year Perspective for Disease Modelling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Drug Development & Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Drug Development & Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 30: World 16-Year Perspective for Drug Development & Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Stem Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 33: World 16-Year Perspective for Stem Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 36: World 16-Year Perspective for Tissue Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Toxicology Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 39: World 16-Year Perspective for Toxicology Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 40: World Mesenchymal Stem Cells (MSC) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2023 & 2030
  • JAPAN
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2023 & 2030
  • CHINA
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: China 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: China 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2023 & 2030
  • EUROPE
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Mesenchymal Stem Cells (MSC) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2023 & 2030
  • FRANCE
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: France 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: France 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2023 & 2030
  • GERMANY
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: Germany 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Italy 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 89: Italy Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Italy Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Italy 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: UK 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 95: UK Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: UK Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: UK 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Mesenchymal Stem Cells (MSC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 110: Rest of World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Rest of World Historic Review for Mesenchymal Stem Cells (MSC) by Application - Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: Rest of World 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Application - Percentage Breakdown of Value Sales for Disease Modelling, Drug Development & Discovery, Stem Cell Banking, Tissue Engineering, Toxicology Studies and Other Applications for the Years 2014, 2023 & 2030
    • TABLE 113: Rest of World Recent Past, Current & Future Analysis for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Rest of World Historic Review for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: Rest of World 16-Year Perspective for Mesenchymal Stem Cells (MSC) by Source of MSC Isolation - Percentage Breakdown of Value Sales for Bone Marrow, Adipose Tissues, Fetal Liver, Lung, Cord Blood and Other Sources of MSC Isolation for the Years 2014, 2023 & 2030

IV. COMPETITION